Genentech’s faricimab meets in Phase III diabetic macular edema trialsThe Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said faricimab met its primary endpoint of non-inferior visual acuity gains versus aflibercept in the global Phase III...

Grail piloting cancer blood test with NHS EnglandGrail Inc. announced a pilot program with NHS England using the company's Galleri blood test to monitor 140,000 asymptomatic participants aged 50 to 79 for three years, and...

Former BARDA Director Bright leaving NIH Rick Bright, the former director of the Biomedical Advanced Research and Development Authority and HHS deputy assistant secretary for preparedness and response, has resigned from NIH, according to a...

As partnerships aimed at preventing COVID-19 or treating early disease continue to form and expand, CSL has begun testing a blood coagulation factor inhibitor for severe COVID-19. The CSL Behring unit of CSL Ltd. (ASX:CSL)...

A slew of therapies entered the clinic this week aimed at tamping down the immune system to treat excessive lung inflammation in COVID-19 patients, even as BARDA announced it would no longer fund the class...

A COVID-19 mAb from Eli Lilly and AbCellera has become the first against the virus to start human trials and is also the Vancouver-based company’s first product to enter the clinic. While the Phase I...

ChemoCentryx therapy fails Phase II study in rare renal disorder ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study...

Editas Medicine Inc. (NASDAQ:EDIT) disclosed in an SEC filing that Judith Abrams resigned as CMO. The gene editing company did not immediately respond to a request for comment on its succession plans for the post....

With positive initial data for Ayvakit in indolent systemic mastocytosis, Blueprint is moving into position to expand its only approved drug into a much larger patient population while sticking to its strategy of focusing on...

Novartis’ Eylea competitor approved FDA approved Beovu brolucizumab-dbll from Novartis AG (NYSE:NVS; SIX:NOVN) to treat wet age-related macular degeneration. In the Phase III HAWK and HARRIER trials, the anti-VEGF single-chain antibody fragment led to vision...